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Abstract 
Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or mal‑
function. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional 
proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis 
undergo inherent constraints that limit regular large‑scale production, recombinant DNA technologies have rap‑
idly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell 
factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and 
especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human 
cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by 
recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency 
towards engineered versions with improved performance and new functionalities regarding the conventional, plain 
protein species. This trend is exemplified by the examination of the contemporary protein‑based drugs developed for 
cancer treatment.
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Background
Human cells produce thousands of proteins that inte-
grated into an extremely complex physiologic network 
perform precise actions as catalysers, signalling agents 
or structural components. Then, dysfunction of proteins 
with abnormal amino acid sequences or the absence of a 
given protein often results in the development of severe 
pathologies such as diabetes [1], dwarfism [2], cystic 
fibrosis [3], thalassaemia [4] or impaired blood clotting 
[5], among many others [6, 7]. In the absence of stand-
ardized gene therapy treatments that would genetically 
reconstitute functional protein production within the 
patient, protein deficiencies must be treated by the punc-
tual or repeated clinical administration of the missing 
protein, so as to reach ordinary functional concentra-
tions. These therapeutic proteins are produced ex  vivo 
mostly in biological systems [8], which must guarantee 
not only full protein functionalities but also a cost-effec-
tive industrial fabrication and the absence of hazardous 
contaminants. Protein drugs have to necessarily conform 
to quality constrains stricter than those expected in the 
production of enzymes for chemical industries, which 
consequently defines the choice of recombinant hosts, 
protocols and production strategies. Nowadays, there are 
over 400 marketed recombinant products (peptides and 
proteins) and other 1300 are undergoing clinical trials 
(figures updated on May 2015 [9]).
In this context of expanding protein drug markets, 
there is a generic consensus about the need to enable 
drugs for cell- or tissue-targeted delivery to reduce doses, 
production costs and side effects. While increasing pro-
tein stability in  vivo can be reached by discrete modifi-
cations in the amino acid sequence, generating fusions 
between therapeutic proteins and specific peptide ligands 
or antibodies that interact with particular cell receptors 
might allow acquiring specificity in the delivery process. 
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In this regard and also pushed by the convenience to 
combine diagnosis and therapy in theranostic agents [10, 
11], contemporary research on protein pharmaceuticals 
tends towards engineered versions functionally more 
sophisticated than plain natural polypeptides.
Review
Cell factories
Since early recombinant DNA times, ever-increasing 
understanding of cell physiology and stress, and of fac-
tors involved in heterologous gene expression and pro-
tein production empowered the use of different living 
factories, namely prokaryotic and eukaryotic cells, plants 
or animals [12, 13]. By using these systems, recombi-
nant production solves source availability problems, is 
considered a bio-safe and green process and confers the 
ability to modify amino acid sequences and therefore 
protein function, to better adjust the product to a desired 
function [14]. There is a wide and growing spectrum of 
expression systems that are becoming available for the 
production of recombinant proteins [15, 16]. Escherichia 
coli was the prevalent platform when the biopharmaceu-
tical sector emerged in the 1980s, and it was followed by 
the implementation of the yeast Saccharomyces cerevi-
siae. Both systems and the associated genetic method-
ologies exhibit an unusually high versatility, making them 
adaptable to different production demands [17]. Despite 
the exploration of insect cells as initially successful sys-
tem especially for vaccine-oriented proteins, mammalian 
cell lines (most notably CHO cells) are nowadays the pre-
vailing animal-derived cell system due to their suitability 
to produce conveniently glycosylated proteins [18, 19] 
(Fig. 1). The ability to carry out post translational modifi-
cations contrasts with complex nutritional requirements, 
slow growth and fragility, and relatively high produc-
tion timing and costs. Thus, among many conventional 
and emerging cell-based systems for protein produc-
tion, bacteria, yeast and mammalian cell lines are the 
most common in biopharma, and both prokaryotic and 
eukaryotic systems are constantly evolving and compet-
ing to improve their properties and intensify as platforms 
of choice for protein drug production [14]. While bacte-
ria has lost its early leading role in the field [19], about 
30 % of marketed biopharmaceuticals are still produced 
in this system [20], as supported by the unusual physi-
ological and genetic manipulability of prokaryotic cells 
[21].
In fact, the main purpose in the development of new 
protein production platforms is to enhance drug func-
tionality through reaching successful protein folding and 
post-translational modifications, while keeping the low 
complexity and high flexibility associated to prokaryotic 
cell culture. In this context, Gram-positive bacteria such 
as Bacillus megaterium [22] and Lactococcus lactis [23] 
allow efficient protein secretion in absence of endotoxic 
cell wall components, while filamentous fungi (such as 
Trichoderma reesei, [24]), moss (Physcomitrella patens, 
[25, 26]) and protozoa (Leishmania tarentolae, [27–29]) 
promote glycosylation patterns similar to those in mam-
malian proteins but being still cultured through methods 
simpler than those required by mammalian cells. Exten-
sive descriptions of emerging (bacterial and non-bacte-
rial) platforms specifically addressed to the production 
of high quality protein drugs can be found elsewhere [15, 
16, 21]. The recent development of an endotoxin-free 
strain of E. coli [30] and its application to the fabrica-
tion of proteins and protein materials [30–32] paves the 
road for a cost-efficient and versatile production of pro-
teins intended for biomedical uses by skipping endotoxin 
removal steps, thus gaining in biosafety and reducing 
production costs [33]. Hopefully, all these new systems 
would soon offer improved products in still simple and 
fully controlled biofabrication approaches.
Trends in protein biopharmaceuticals
Nearly 400 recombinant protein-based products have 
been successfully produced and are approved as biop-
harmaceuticals [9], a term that refers to therapeutic 
products generated by technologies that involve living 
organisms [34]. Other 1300 protein candidates are under 
development, of which around 50  % are in pre-clinical 
studies and other 33 % in clinical trials [9] (Fig. 2). In this 
context, an increase in the number of approvals in next 
years is predictable. Developed by Eli Lilly & Co in the 
70’s, Humulin, a recombinant human insulin fabricated 
in the bacterium E. coli [35], was the first approved biop-
harmaceutical (by the FDA) in 1982 [36, 37]. Other natu-
ral proteins such as hormones, cytokines and antibodies 
(Orthoclone OKT3) were among the single nine products 
approved in 1980s (Table 1). Nowadays, the therapeutic 
areas that have benefited more from recombinant biop-
harmaceuticals are metabolic disorders (e.g. diabetes 
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Fig. 1 Number of recombinant protein products approved for use as 
drugs in humans, depending on the type of production platform
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type 1, type 2, obesity or hypoglycaemia), haematologi-
cal disorders (e.g. renal anaemia, haemophilia A, bleed-
ing or clotting disorders) and oncology (e.g. melanoma, 
breast or colorectal cancer), with 24, 18 and 15 % of the 
approvals respectively (Fig. 3). In this regard, oncology is 
a clearly expanding market. In the period 2010–2014, 9 
out of 54 approved biopharmaceuticals were antitumoral 
drugs, cancer representing the most common indica-
tion within this period. Digging into the molecular bases 
of biopharmaceuticals, there is a clear trend towards 
antibody-based products. Over the same period (2010–
2014), 17 of the 54 protein drugs approved were mono-
clonal antibodies (31.5  %), compared with 11  % over 
1980–1989 [22]. Furthermore, among the top ten selling 
protein biopharmaceuticals globally in 2014 (Table  2), 
six are antibodies or antibody-derived proteins (Humira, 
Remicade, Rituxan, Enbrel, Avastin, Herceptin; http://
qz.com/349929/best-selling-drugs-in-the-world/).   
Formerly, biopharmaceuticals were recombinant ver-
sions of natural proteins, with the same amino acid 
sequence as the respective native versions (with only 
minor modifications, often resulting from the cloning 
strategy). Since 1990s, a meaningful proportion of the 
approvals are based on highly modified forms of recom-
binant proteins. This novel alternative, based on protein 
or domain fusion and on truncated versions, offers a wide 
spectrum of possible combinations to obtain novel biop-
harmaceuticals with different joined activities that are 
not found together in nature.
Protein drugs for cancer treatment
Oncology is one of the therapeutic indications that domi-
nate the biopharmaceutical market, as cancer is a major 
cause of morbidity and mortality worldwide. Surgery and 
radiotherapy are effective in curing cancer at early dis-
ease stages; however, they cannot eradicate metastatic 
disease. The presence of micrometastases or clinically 
evident metastases at diagnosis requires their use in com-
bination with genotoxic chemotherapy to increase cure 
rates [38]. Nevertheless, the success of chemotherapy 
has been hampered because of its lack of selectivity and 
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Fig. 2 Workflow involved in the development of a new drugs and 
approximate percentage (bars and numbers) of recombinant proteins 
currently in each step [9]
Table 1 Recombinant biopharmaceuticals approved in the 1980s
Product Cell factory Therapeutic indication Year
Humulin E. coli Diabetes 1982
Protropin E. coli hGH deficiency 1985
Roferon A E. coli Hairy cell leukaemia 1986
IntronA E. coli Cancer, genital warts and hepatitis 1986
Recombivax S. cerevisiae Hepatitis B 1986
Orthoclone OKT3 Hybridoma cell line Reversal of acute kidney and transplant rejection 1986
Humatrope E. coli hGH deficiency 1987
Activase CHO Acute myocardial infarction 1987
Epogen CHO Anaemia 1989
24 % 
18 % 
15 % 
8 % 
6 % 
5 % 
5 % 
19 % 
Metabolic disorders
Haematological disorders
Oncology
Women health
Immunology
Infecous disease
Men health
Others
Fig. 3 Amount of marketed recombinant proteins (expressed in per‑
centages) applied to each therapeutic area. Coloured in pink, other 
therapeutic areas (<5 % each) include diseases related to cardiology, 
central nervous system, ophthalmology and dermatology among 
others
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specificity, so that the toxicity to normal tissues limits the 
dose that could be administered to patients. The develop-
ment of biopharmaceuticals capable of inhibiting specific 
molecular targets driving cancer (for instance, monoclo-
nal antibodies anti-Her2—Trastuzumab- or anti-VEGF—
Bevacizumab-) goes in this direction [39].
Among marketed protein biopharmaceuticals, almost 
24  % (94 products) are used in antitumoral therapies. 
Most of these products are used for supportive purposes 
intended to minimize the side effects of chemotherapy, 
usually neutropenia or anaemia (some representative 
examples are shown in Table 3). Nineteen out of those 94 
products are true antitumoral drugs, 69  % of which are 
produced in E. coli (Fig. 4) and are based on engineered 
amino acidic sequences, protein fusions and single pro-
tein domains (Table 4).
Clearly, modified protein versions are the most abun-
dant in cancer therapies over natural polypeptides. As 
relevant examples, Ziv aflibercept is a recombinant fusion 
protein produced in CHO cells used against colorectal 
cancer. It consists of portions of each Vascular Endothelial 
Growth Factor Receptors (VEGFR1 and VEGFR2) fused 
Table 2 Top ten selling protein biopharmaceuticals in 2014
a Data according to www.medtrack.com, November 2015
Druga Active ingredient Molecule Sales in  
billions
Origin
Humira Adalimumab Recombinant human monoclonal antibody 12.54 CHO
Sovaldi Sofosbuvir Nucleotide analogue polymerase (NS5B) inhibitor 10.28 Chemical
Remicade Infliximab Recombinant chimeric, humanized tumor necrosis 
factor alpha (TNF) monoclonal antibody
9.24 Hybridoma cell line
Rituxan Rituximab Recombinant humanized monoclonal antibody 8.68 CHO
Enbrel Etanercept Recombinant soluble dimeric fusion protein 8.54 CHO
Lantus Insulin glargine Insulin receptor agonist 7.28 E. coli
Avastin Bevacizumab Recombinant humanized antibody 6.96 CHO
Herceptin Trastuzumab Recombinant humanized monoclonal antibody 6.79 CHO
Advair Fluticasone propionate and salmeterol xinafoate Glucocorticoid receptor agonist and β‑2 adrenergic 
receptor agonist
6.43 Chemical
Crestor Rosuvastatin calcium Antihyperlipedemic agent 5.87 Synthetic
Table 3 Representative examples of supportive protein drugs in cancer
Drug name Cell factory Biological 
role
Mechanism of action Indications
Filgrastim (Scimax) E. coli Cytokine Stimulates hematopoiesis Bone marrow transplantation and cancer 
chemotherapy induced neutropenia
Pegfilgrastim (Neupeg) E. coli Cytokine Stimulates differentiation, proliferation and 
activation of the neutrophilic granulocytes
Cancer chemotherapy induced neutropenia
Darbepoetin alfa (Aranesp) CHO cells Hormone Stimulates processes of erythropoiesis or red 
blood cell production
Anemia associated with chronic renal failure, 
cancer chemotherapy or heart failure. 
Myelodysplastic syndrome
Lenograstim (CERBIOS) CHO cells Cytokine Stimulates differentiation, proliferation and 
activation of neutrophilic granulocytes
Neutropenia associated with cytotoxic 
therapy or bone marrow transplantation
Epoetin alfa (Binocrit) CHO cells Hormone Stimulates production of oxygen carrying  
red blood cells from the bone marrow
Anemia associated with chronic renal 
failure and cancer chemotherapy induced 
anemia
69%
26%
5%
E. coli
Mammalian cells
S. cerevisiae
Fig. 4 Cell factories used for the production of recombinant biophar‑
maceuticals against cancer (expressed in percentages)
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to the constant fraction (Fc) of a human IgG1 immuno-
globulin (Fig. 5). This construct acts as a decoy by binding 
to VEGF-A, VEGF-B and placental growth factor (PlGF), 
which activate VEGFR. This trap hinders the interaction 
between the growth factors and the receptors, inhibiting 
the VEGF pathway which is involved in the angiogenic 
process [40]. Denileukin diftitox is a recombinant pro-
tein composed of two diphtheria toxin fragments (A and 
B) and a human interleukin-2 (Fig. 5). Diphteria toxin is a 
potent exotoxin secreted by Corynebacterium diphteriae. 
Due to its peculiar structure, the whole complex, pro-
duced in E. coli, is capable of delivering a cytotoxic agent 
directly to a specific target. There are two main active 
blocks whose function is firstly to selectively deliver the 
biopharmaceutical (IL-2) and secondly cause cytotoxicity 
(toxin A and B) [41]. The fusion protein binds to the IL-2 
receptor, which is expressed in cancerous cells (cutaneous 
T cell lymphoma). Once the toxin moiety is internalized, 
the catalytic domain promotes cell death through protein 
synthesis inhibition [42].
Table 4 Anticancer recombinant biopharmaceuticals approved until March 2015
Drug name Cell factory Source Biological role Indications
Denileukin diftitox E. coli Fusion protein Diphtheria toxin fused  
to cytokine
Cutaneous T‑cell lymphoma
Endostatin E. coli Modified Collagen derivative Non‑small cell lung cancer, metastatic 
colorectal cancer
Aldesleukin E. coli Modified Cytokine Metastatic renal cell carcinoma, 
metastatic melanoma, kidney cancer, 
angiosarcoma
Interleukin‑2 E. coli Modified Cytokine Metastatic melanoma, metastatic renal 
cell carcinoma
Filgrastim E. coli Modified Cytokine Acute lymphocytic leukaemia, solid 
tumour
Interferon alpha‑2a E. coli Modified Cytokine AIDS‑related Kaposi’s sarcoma, follicular 
lymphoma, cutaneous T‑cell lym‑
phoma, melanoma, chronic myelo‑
cytic leukaemia, hairy cell leukaemia, 
renal cell carcinoma, kidney cancer
Interferon alpha‑2b E. coli Modified Cytokine AIDS‑related Kaposi’s sarcoma, pancre‑
atic endocrine tumour, melanoma, 
non‑Hodgkin lymphoma, leukae‑
mia, hairy cell leukaemia, renal cell 
carcinoma, multiple myeloma, CML, 
follicular lymphoma, melanoma
Interferon alpha‑1b E. coli Modified Cytokine Renal cell carcinoma, hairy cell leukae‑
mia
Interferon gamma‑1a E. coli Modified Cytokine Kidney cancer, sezary syndrome, myco‑
sis fungoides
Tasonermin E. coli Natural Cytokine Soft tissue sarcoma
Molgramostim E. coli Modified Growth factor Myelodysplastic syndrome
Nartograstim E. coli Modified Growth factor Solid tumour
Palifermin E. coli Fraction Growth factor Metastatic renal cell carcinoma, meta‑
static melanoma
Sargramostim S. cerevisiae Modified Growth factor Acute myelocytic leukaemia
Ziv‑aflibercept CHO cells Fusion protein Growth factor receptor  
fused to IgG1
Metastatic colorectal cancer
Thyrotropin alpha CHO cells Modified Hormone Thyroid cancer
Trastuzumab biosimilar CHO cells Modified Monoclonal antibody Breast cancer, gastric cancer, metastatic 
breast cancer
Rituximab biosimilar CHO cells Modified Monoclonal antibody Non‑Hodgkin lymphoma, chronic 
lymphocytic leukaemia
Interferon alpha Human lymphoblastoid  
cells
Modified Cytokine AIDS‑related Kaposi’s sarcoma, multiple 
myeloma, non‑Hodgkin lymphoma, 
CML, hairy cell leukaemia, renal cell 
carcinoma
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As targeted drug delivery for cancer is a most recent and 
expanding area of research, other non-recombinant, pro-
tein-based biopharmaceuticals are also heavily represented. 
Those mainly include antibody-drug conjugates (ADCs) 
such as Brentuximab vedotin, Trastuzumab emtansine, or 
nanoparticle-drug conjugates such as nab-paclitaxel [39, 
43]. In these cases, the protein counterpart acts as a tar-
geted vehicle for conventional chemical drugs. Again, this 
approach pursues the selective drug delivery to specific tar-
get cells, aimed to increase antitumoral activity while reduc-
ing toxicity on normal cells and the associated side effects.
Products against cancer that provided the high-
est revenues in 2013 are represented in Fig.  6. Sixty 
percent of those products are recombinant proteins, 
supporting the idea that recombinant protein produc-
tion is still a rising and promising platform, offering 
room for important advances in the biopharmaceutical 
sector.
Conclusions
In summary, the market and potential for recombinant 
drugs is expanding by taking advantage of a steady grow-
ing spectrum of protein production platforms. Despite 
the strength of mammalian cell lines as factories, micro-
bial cells and specially E. coli are still potent protein 
factories essentially supported by their versatility and 
cost-effective cultivation. Recombinant drugs are mov-
ing from plain recombinant versions of natural products 
to more sophisticated protein constructs resulting from 
a rational design process. Combining protein domains 
to gain new functionalities is being exploited in drug 
discovery by exploiting the structural and functional 
versatility that merge in proteins as extremely versatile 
macromolecules.
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Fig. 5 Schematic molecular structure of two marketed recombinant 
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